<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092581</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2114</org_study_id>
    <secondary_id>2021-004535-84</secondary_id>
    <nct_id>NCT05092581</nct_id>
  </id_info>
  <brief_title>COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19</brief_title>
  <official_title>A Phase 1b, Open-Label, Single Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:&#xD;
&#xD;
        -  To characterize the concentrations of casirivimab+imdevimab in serum over time&#xD;
&#xD;
        -  To evaluate the safety and tolerability of casirivimab+imdevimab&#xD;
&#xD;
      The secondary objective of the study is:&#xD;
&#xD;
      • To assess the immunogenicity of casirivimab+imdevimab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">June 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of casirivimab+imdevimab in serum over time</measure>
    <time_frame>Through day 169</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with treatment-emergent serious adverse events (SAEs)</measure>
    <time_frame>Through day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with infusion-related reactions</measure>
    <time_frame>Through day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with hypersensitivity reactions</measure>
    <time_frame>Through day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to casirivimab+imdevimab over time</measure>
    <time_frame>Through day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutralizing antibodies (NAb) to casirivimab+imdevimab over time</measure>
    <time_frame>Through day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>casirivimab+imdevimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>casirivimab+imdevimab</intervention_name>
    <description>Single dose weight-based equivalent administered intravenously (IV)</description>
    <arm_group_label>casirivimab+imdevimab</arm_group_label>
    <other_name>REGN-COV2</other_name>
    <other_name>REGN10933</other_name>
    <other_name>REGN10987</other_name>
    <other_name>REGEN-COV™</other_name>
    <other_name>Ronapreve™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Has SARS-CoV-2 positive antigen or molecular diagnostic test ≤72 hours prior to study&#xD;
             enrollment Note: historical record of positive result is acceptable as long as the&#xD;
             sample was collected ≤72 hours prior to enrollment&#xD;
&#xD;
          2. Has symptoms consistent with COVID-19, as determined by the investigator, with onset ≤&#xD;
             14 days before dosing&#xD;
&#xD;
          3. Hospitalized due to COVID-19&#xD;
&#xD;
          4. Provide informed consent signed by study patient or legally acceptable&#xD;
             representative/guardian&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, unlikely to survive for &gt;96 hours from screening&#xD;
&#xD;
          2. Neonates having gestational age of &lt;29 weeks and weight &lt;1.1 kg&#xD;
&#xD;
          3. Receiving extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          4. Has new-onset stroke or seizure disorder during hospitalization&#xD;
&#xD;
          5. Initiated on renal replacement therapy due to COVID-19&#xD;
&#xD;
          6. Has circulatory shock requiring vasopressors on dosing day Note: Patients who require&#xD;
             vasopressors for sedation-related hypotension or reasons other than circulatory shock&#xD;
             may be eligible in this study&#xD;
&#xD;
          7. Participation in a clinical research study, including any double-blind study,&#xD;
             evaluating an investigational product within 30 days and less than 5 half-lives of the&#xD;
             investigational product prior to the screening visit&#xD;
&#xD;
          8. Members of the clinical site study team and/or their immediate family&#xD;
&#xD;
          9. Plans to receive an investigational or approved SARS-CoV-2 vaccine within 90 days&#xD;
             after study drug administration based on current Centers for Disease Control&#xD;
             vaccination guidelines (CDC, 2021). Refer to the latest CDC guidance for any updates.&#xD;
&#xD;
             Note: Patients who have already completed vaccination prior to study enrollment may be&#xD;
             allowed in the study.&#xD;
&#xD;
         10. Prior use (within 90 days prior to study drug administration) or current use of any&#xD;
             investigational, authorized, or approved passive antibody for prophylaxis of&#xD;
             SARS-CoV-2 infection, including convalescent plasma, convalescent sera, hyperimmune&#xD;
             globulin, or other monoclonal antibodies (eg, bamlanivimab and etesevimab, sotrovimab)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/ Exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

